英文原题:Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.
阴茎鳞状细胞癌(PSCC)是一种罕见且侵袭性强的泌尿生殖系统恶性肿瘤,需要多学科综合管理。
阴茎鳞状细胞癌(PSCC)是一种罕见且侵袭性强的泌尿生殖系统恶性肿瘤,需要综合多学科管理。本叙述性综述提供了PSCC诊断和治疗路径的最新概述,涵盖从以手术为治疗基石的局限性疾病,到需要化疗和放疗与手术相结合的多模式策略的局部晚期疾病,最后到以全身治疗为主要治疗手段的转移性疾病。以铂类为基础的化疗仍然是晚期PSCC既定的全身治疗骨架,而免疫检查点抑制剂、化疗-免疫治疗联合方案、靶向治疗、抗体-药物偶联物、疫苗和过继性细胞治疗则代表了有初步证据支持的研究性策略。尽管这些方法已显示出早期活性信号,但其常规整合到临床实践中仍受限于研究规模小且异质性大、缺乏确定性随机证据,以及需要在明确界定的临床和分子亚组中进行前瞻性验证。因此,本综述旨在提供一种按分期调整的、多学科的PSCC当代治疗策略概述。
Penile squamous cell carcinoma (PSCC) is a rare and aggressive genitourinary malignancy requiring integrated multidisciplinary management. This narrative review provides an updated overview of the diagnostic and therapeutic pathway of PSCC from localized disease, where surgery remains the cornerstone of treatment, to locally advanced disease, where multimodal strategies integrating chemotherapy and radiotherapy with surgery are required, and finally to metastatic disease, where systemic therapy becomes the mainstay of treatment. Platinum-based chemotherapy remains the established systemic backbone for advanced PSCC, whereas immune checkpoint inhibitors, chemo-immunotherapy combinations, targeted therapies, antibody-drug conjugates, vaccines, and adoptive cellular therapies represent investigational strategies supported by preliminary evidence. Although these approaches have shown early signals of activity, their routine integration into clinical practice remains limited by small and heterogeneous studies, the lack of definitive randomized evidence, and the need for prospective validation in well-defined clinical and molecular subgroups. The aim of this review is therefore to provide a stage-adapted and multidisciplinary overview of therapeutic strategies for the contemporary management of PSCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。